Search Results - "Zatelli, M. C"

Refine Results
  1. 1

    Tumour-induced osteomalacia: 18 months of 2-weekly burosumab treatment by Aliberti, L, Gagliardi, I, Pontrelli, M, Zatelli, M C, Ambrosio, M R

    “…Summary Tumour-induced osteomalacia (TIO) is due to an overproduction of fibroblast growth factor 23 (FGF23) by mesenchymal tumours, causing hypophosphatemia,…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT by ZATELLI, Maria C, TAGLIATI, Federico, TAYLOR, John E, ROSSI, Roberta, CULLER, Michael D, DEGLI UBERTI, Ettore C

    “…Somatostatin and its receptors (SSTR1 to SSTR5) are expressed in normal human parafollicular C cells and medullary thyroid carcinoma (MTC), but the role of…”
    Get full text
    Journal Article
  4. 4

    Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line by Gentilin, E., Borges De Souza, P., Ambrosio, M. R., Bondanelli, M., Gagliardi, I., Zatelli, M. C.

    Published in Journal of endocrinological investigation (01-12-2023)
    “…Purpose Clinical control of corticotroph tumors is difficult to achieve since they usually persist or relapse after surgery. Pasireotide is approved to treat…”
    Get full text
    Journal Article
  5. 5

    Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review by Isidori, Andrea M, Sbardella, Emilia, Zatelli, Maria Chiara, Boschetti, Mara, Vitale, Giovanni, Colao, Annamaria, Pivonello, Rosario

    “…Context: Ectopic Cushing's Syndrome (ECS) can be a diagnostic challenge with the hormonal source difficult to find. This study analyzes the accuracy of imaging…”
    Get full text
    Journal Article
  6. 6

    Investigation of COVID-19 infection in subjects with Klinefelter syndrome by Aliberti, L., Gagliardi, I., Lupo, S., Verrienti, M., Bondanelli, M., Zatelli, M. C., Ambrosio, M. R.

    Published in Journal of endocrinological investigation (01-05-2022)
    “…Purpose COVID-19 has worse clinical outcomes in males compared with females and testosterone may determine gender differences. Hypogonadism and supernumerary X…”
    Get full text
    Journal Article
  7. 7

    Thyroid nodule recurrence following lobo-isthmectomy: incidence, patient’s characteristics, and risk factors by Zatelli, M. C., Lamartina, L., Meringolo, D., Arvat, E., Damiani, L., Grani, G., Nervo, A., Durante, C., Giacomelli, L.

    Published in Journal of endocrinological investigation (01-12-2018)
    “…Purpose This study was aimed at assessing the incidence and timing of thyroid nodules recurrence, defined as appearance of new benign or malignant nodules in…”
    Get full text
    Journal Article
  8. 8

    Clinico–pathological features, treatments and survival of malignant insulinomas: a multicenter study by Veltroni, A, Cosaro, E, Spada, F, Fazio, N, Faggiano, A, Colao, A, Pusceddu, S, Zatelli, M C, Campana, D, Piovesan, A, Pia, A, Grossrubatscher, E M, Filice, A, Bianchi, A, Razzore, P, Toaiari, M, Cingarlini, S, Landoni, L, Micciolo, R, Davì, M V

    Published in European journal of endocrinology (01-04-2020)
    “…Introduction Management of malignant insulinomas is challenging due to the need to control both hypoglycaemic syndrome and tumor growth. Literature data is…”
    Get full text
    Journal Article
  9. 9

    Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro by Zatelli, M C, Piccin, D, Tagliati, F, Bottoni, A, Ambrosio, M R, Margutti, A, Scanarini, M, Bondanelli, M, Culler, M D, Uberti, E C degli

    Published in Journal of molecular endocrinology (01-10-2005)
    “…Dopamine (DA) and somatostatin (SRIF) receptor agonists inhibit growth hormone (GH) secretion by pituitary adenomas. We investigated DA subtype 2 receptor…”
    Get full text
    Journal Article
  10. 10

    GH/IGF-1 axis in a large cohort of ß-thalassemia major adult patients: a cross-sectional study by Gagliardi, I., Mungari, R., Gamberini, M. R., Fortini, M., Dassie, F., Putti, M. C., Maffei, P., Aliberti, L., Bondanelli, M., Zatelli, M. C., Ambrosio, M. R.

    Published in Journal of endocrinological investigation (01-07-2022)
    “…Purpose GH deficit (GHD) could represent an endocrine issue in ß-Thalassemia Major (ßTM) patients. GH/IGF-1 axis has not been extensively explored in ßTM…”
    Get full text
    Journal Article
  11. 11

    Combination of ultrasound and molecular testing in malignancy risk estimate of Bethesda category IV thyroid nodules: results from a single-institution prospective study by Marina, M., Zatelli, M. C., Goldoni, M., Del Rio, P., Corcione, L., Martorana, D., Percesepe, A., Bonatti, F., Mozzoni, P., Crociara, A., Ceresini, G.

    Published in Journal of endocrinological investigation (01-12-2021)
    “…Purpose Malignancy prediction in indeterminate thyroid nodules is still challenging. We prospectively evaluated whether the combination of ultrasound (US) risk…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14
  15. 15

    A tool to predict survival in stage IV entero-pancreatic NEN by Tarquini, M., Ambrosio, M. R., Albertelli, M., de Souza, P. B., Gafà, R., Gagliardi, I., Carnevale, A., Franceschetti, P., Zatelli, M. C.

    Published in Journal of endocrinological investigation (01-06-2021)
    “…Purpose Well-differentiated stage IV neuroendocrine neoplasms (NEN) have an extremely heterogeneous, unpredictable clinical behavior. Survival prognostic…”
    Get full text
    Journal Article
  16. 16

    Acromegaly secondary to an incidentally discovered growth-hormone-releasing hormone secreting bronchial carcinoid tumour associated to a pituitary incidentaloma by Verrua, E, Ronchi, C. L, Ferrante, E, Ferrari, D. I, Bergamaschi, S, Ferrero, S, Zatelli, M. C, Branca, V, Spada, A, Beck-Peccoz, P, Lania, A. G

    Published in Pituitary (01-09-2010)
    “…In this report we emphasize the opportunity of considering the uncommon causes of chronic GH-excess in the initial diagnostic process, such as GHRH…”
    Get full text
    Journal Article
  17. 17
  18. 18

    How to improve effectiveness of pegvisomant treatment in acromegalic patients by Ragonese, M., Grottoli, S., Maffei, P., Alibrandi, A., Ambrosio, M. R., Arnaldi, G., Bianchi, A., Puglisi, S., Zatelli, M. C., De Marinis, L., Ghigo, E., Giustina, A., Maffezzoni, F., Martini, C., Trementino, L., Cannavo, S.

    Published in Journal of endocrinological investigation (01-05-2018)
    “…Purpose Pegvisomant (PEGV) treatment in acromegaly patients resistant to somatostatin analogues is less effective in the real life than in clinical trials…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Communicating the diagnosis of Klinefelter syndrome to children and adolescents: when, how, and who? by Aliberti, L., Gagliardi, I., Bigoni, S., Lupo, S., Caracciolo, S., Ferlini, A., Isidori, A. M., Zatelli, M. C., Ambrosio, M. R.

    Published in Journal of community genetics (01-06-2022)
    “…Klinefelter syndrome (KS) is the most frequent sex chromosome aneuploidy in males. KS diagnosis disclosure has an important impact on diagnosis acceptance and…”
    Get full text
    Journal Article